Global Health Economics and Outcomes Research Fellowship Program Univ of Washington 2020-2022 About Our Company

GLOBAL HEALTH ECONOMICS AND OUTCOMES RESEARCH FELLOWSHIP PROGRAM UNIV OF WASHINGTON 2020-2022 ABOUT OUR COMPANY

Allergan PLC (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. We are focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

We market a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories.

We are an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry with 65+ mid-to-late stage pipeline programs currently in development. Learn more at www.Allergan.com.

OUR WORLD-CLASS MANUFACTURING AND R&D NETWORK

IRELAND UK Clonshaugh Liverpool CANADA Galway Marlow MANUFACTURING Markham Westport R&D BELGIUM USA Liege CHINA Branchburg, NJ FRANCE Beijing Cincinnati, OH Pringy Shanghai Northern CA (Biologics) Pringy Irvine, CA (Biologics) JAPAN Dublin, CA Tokyo Waco, TX Houston, TX COSTA RICA San Jose SINGAPORE Bridgewater, NJ BRAZIL Singapore Irvine, CA Guarulhos Pleasanton, CA São Paulo Sunrise, FL Madison, NJ

GLOBAL HEALTH ECONOMICS AND OUTCOMES RESEARCH (GHEOR)

PRODUCT VALUE PROPOSITION 1 …outcomes research strategy based on product value, stakeholder needs & insights

EVIDENCE GENERATION AND TOOL DEVELOPMENT 2 …through clinical and health economics & outcomes research (HEOR) data

VALUE COMMUNICATION …about evidence informing the value proposition to stakeholders 3 …informs health care decision making

1 GHEOR Fellowship Program 2020-2022 ABOUT OUR SCHOOL

The University of Washington is a world-class leader in health sciences education and has been consistently listed in US News and World Report as one of the top 10 institutions for its graduate programs. The University is particularly noted for its strong research programs and since 1974 has received more federal funds for research and training than any other public university in the United States. It fosters a highly collegial atmosphere between departments and academic units, creating a particularly attractive environment for such partnerships between the public and private sectors.

The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute is housed within the University of Washington School of Pharmacy, which boasts nearly 125 years of academic and research success. Faculty in the program (1) provide advanced research training for graduate students, post-doctoral fellows and clinicians (PharmDs, MDs), (2) conduct rigorous scientific research in economic evaluations and outcomes of pharmaceuticals and other health technologies, and (3) translate and disseminate the results of research into clinical practice and healthcare policy, with the goal of improving patient care.

The CHOICE Institute faculty participating in the fellowship have been chosen both for their dedication to teaching and their excellence in research. Each is trained either as a health economist or health services researcher and all have an extensive history of effective economic evaluations and pharmacoepidemiologic research.

GHEOR Fellowship Program 2020-2022 2 ABOUT OUR FELLOWSHIP The University of Washington/Allergan GHEOR Fellowship is a two-year program that provides training and hands-on experience in a broad-range of health economics and outcomes research topics. The program is structured to allow fellows to gain proficiency in health outcomes strategy and research as conducted in both academic and pharmaceutical industry settings.

THE FELLOWSHIP PROGRAM The University of Washington and Allergan are pleased to offer two, 2-year GHEOR Fellowship positions for the academic year 2020-2022. Fellows will spend their first year at the University of Washington (Seattle, WA), and the second year at Allergan (Irvine, CA). The objective of the first year is to educate fellows on the principles and methods used in health economics and outcomes research. During the second year, fellows are provided with opportunities to gain practical knowledge and experience with the use of clinical, economic, and humanistic data by supporting the development and commercialization of pharmaceutical products. This will be accomplished by participating in work activities undertaken by the GHEOR team.

Compensation includes a competitive stipend, basic medical insurance, conference attendance, relocation from Seattle to Irvine, and holiday/vacation time. A Master’s (MS) Degree is awarded upon completion of all course requirements and thesis project.

FELLOWSHIP DIRECTORS

UNIVERSITY OF WASHINGTON ALLERGAN PLC ALLERGAN PLC Beth Devine, PharmD, MBA, PhD, FASHP, Patrick Gillard, PharmD, MS Amy Tung, PharmD, MS Professor, Director of Graduate Programs Executive Director, General Medicine, Senior Manager, General Medicine, The Comparative Health Outcomes, Policy, Global Evidence and Value Global Evidence and Value and Economics (CHOICE) Institute E-Mail: [email protected] E-Mail: [email protected] E-Mail: [email protected]

3 GHEOR Fellowship Program 2020-2022 FELLOWSHIP STRUCTURE ST YEAR FIRST YEAR OBJECTIVES The objective of the first year is to provide the fellow with the research tools necessary for economic evaluation and policy assessment. The fellow will be given an overview of pharmaceutical economics and general health policy, and taught methods of economic assessment, health services research, epidemiology, clinical research design, and 1 biostatistical analyses. The fellow will be assigned a MS thesis project which is selected based on input from both Allergan as well as the University of Washington mentors. Fellows are highly encouraged to complete their MS project during their first year. Additionally, fellows will also engage in ongoing projects with Allergan throughout their first year, applying skills from previous pharmacy training as well as integrating new techniques developed from University of Washington courses. Applying learning to solve real-world problems is a constant focus of the fellowship.

The fellow’s actual course of study will be developed on an individual basis with the Program Director, Dr. Beth Devine, but will consist of courses in biostatistics, epidemiology, economic evaluations and outcomes research, and health and pharmaceutical policy.

AFTER COMPLETION OF THE FIRST YEAR, THE FELLOW WILL HAVE A CLEAR UNDERSTANDING OF: • General principles of economics and in particular how economics influences the use, cost, and availability of pharmaceuticals. • The complex structure of drug policy and how it determines relationships between consumers, health care providers, insurers, payers, and government agencies. • The breadth and scope of analytical methods needed for the assessment of Patient Reported Outcomes (PROs), economic modeling, retrospective database studies, and observational studies. • Formulary development, maintenance and evaluation in institutional, managed care, and state-level government programs.

GHEOR Fellowship Program 2020-2022 4 ND YEAR SECOND YEAR OBJECTIVES The second year of training will be at Allergan in Irvine, CA with the GHEOR department. This part of the program is designed to allow the fellow to learn about the role of economic evaluations and outcomes research in the drug development and commercialization process within the industry setting. The research may be on an existing or 2 experimental product for a disease state that is of interest to Allergan. In addition to completing individual research project(s), fellows will participate in ongoing economic evaluations, outcomes research, and other projects in collaboration with the GHEOR team. These experiences will provide the fellow with opportunities to interact with team members in other departments at Allergan to learn how economic analyses and outcomes research are used throughout the pharmaceutical industry. Fellows will see firsthand how outcomes research is utilized to demonstrate the place of Allergan products in treatment pathways and its value.

5 GHEOR Fellowship Program 2020-2022 ALLERGAN FELLOWSHIP MENTORS

David Macarios, Sepideh Varon, Jonathan W. Kowalski, Joanna Campbell, Patrick Gillard, MBA, MSc PhD PharmD, MS PhD PharmD, MS Vice President, GEV Vice President, GHEOR Vice President, US HOV Executive Director, GHEOR Executive Director, GHEOR

Vaishali Patel, Hema Viswanathan, Kate Burslem, Katelyn Keyloun, Vanessa Shih, PharmD, MS BPharm, PhD MSc PharmD, MS PharmD, MS Executive Director, GHEOR Executive Director, GHEOR Executive Director, GHEOR Associate Director, GHEOR Associate Director, GHEOR

Anand Shewale, Amanda Harrington, Amy Tung, Sarah Baradaran, Elaheh Shirneshan, MS, PhD PhD PharmD, MS PharmD, MS PhD Associate Director, GHEOR Associate Director, GHEOR Senior Manager, GHEOR Senior Manager, GHEOR Senior Manager, GHEOR UNIVERSITY OF WASHINGTON PROGRAM FACULTY • Anirban Basu, PhD • Thomas K. Hazlet, • Aasthaa Bansal, PhD Professor and Stergachis Family Endowed PharmD, Dr. PH Associate Professor Director of The CHOICE Institute Associate Professor • Andy Stergachis, BPharm, PhD • Beth Devine, PharmD, MBA, • Scott D. Ramsey, MD, PhD Professor and Associate Dean for Research, PhD, FASHP Professor Graduate Programs and New Initiatives Professor, Director of Graduate Programs • Sean D. Sullivan, PhD • Douglas Barthold, PhD • Josh Carlson, MPH, PhD Professor and Dean of Research Assistant Professor Associate Professor School of Pharmacy • Shelly Gray, PharmD, MS • Louis P. Garrison, Jr., PhD • David L. Veenstra, Professor Professor Emeritus PharmD, PhD Professor and Associate Director of • Zachary Marcum, PharmD, • Ryan Hansen, PhD, PharmD The CHOICE Institute MS, PhD Assistant Professor Assistant Professor • Joseph Babigumira, MBChB, MS, PhD Adjunct Associate Professor

GHEOR Fellowship Program 2020-2022 6 CURRENT FELLOWS ST YEAR FELLOWS BRENNAN BEAL, PHARMD Brennan is a first year UW/Allergan Health Economics and Outcomes Research (HEOR) fellow. Prior to his fellowship, Brennan earned his PharmD from the University of North Carolina Eshelman School of Pharmacy. There he conducted research within the Department of Pharmaceutical Outcomes and Policy (DPOP) as well as the Center for Medication Optimization (CMO), where he worked to understand the cost of embedding 1 pharmacists in primary care settings. While completing his PharmD, he was also recruited as an independent consultant for local pharmaceutical firms modeling expected value and product uptake from various marketing scenarios.

Brennan is humbled to be joining the CHOICE institute to learn from the exceptional faculty and hone his skills in economic modeling and outcomes research. For his thesis, he will be performing a large database research project to understand caregiver burden for age-related macular degeneration

JAE HYUN LEE, PHARMD Jae Hyun Lee earned his PharmD from the University of Illinois at Chicago (UIC), College of Pharmacy. During his time in pharmacy school, he assisted the UIC ICER team with the literature search for the report on Calcitonin Gene-Related Peptide Inhibitors. In addition, he was a rotation student at AbbVie where he forecasted the financial impact that new competitors may have on the company’s hepatitis C portfolio, specifically in the Medicare and Medicaid population. He also worked as a managed care research assistant for Dymaxium where he created monographs for medications nearing their FDA approval dates.

Jae is excited to join the CHOICE Institute and work with the faculty to develop his research skills in HEOR. For his thesis, he will be using the Medical Expenditure Panel Survey (MEPS) data to assess treatment patterns, adherence, and discontinuation of triptan use in patients with migraines.

7 GHEOR Fellowship Program 2020-2022 ND YEAR FELLOWS ASHLEY KIM, PHARMD, MS Ashley received her PharmD from the University of California, San Francisco. For her first year of the fellowship Ashley worked under the mentorship of Drs. Aasthaa Bansal, Beth Devine, Joshua Roth, and Joanna Campbell. At the University of Washington, she conducted a retrospective claims analysis to characterize the healthcare resource utilization and costs among patients with geographic atrophy for her master’s thesis.

2 In her second year of the fellowship, Ashley has worked in the eye care therapeutic area with projects in glaucoma and age-related macular degeneration. Ashley is looking forward to continuing to utilize her training in outcomes research and economic evaluation on site at Allergan.

ABSTRACTS FROM FELLOWSHIP: 1. Kim A, Devine B, Roth J. Cost-effectiveness of first-line pembrolizumab plus chemotherapy for metastatic squamous non-small cell lung cancer. Journal of Clinical Oncology 37 (15_suppl), 20703-20703 (Online Poster) 2. Kim A, Devine B. Clinical and Economic Burden of Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Systematic Review. UW Corporate Advisory Board Meeting, September 2018, Seattle, WA. (Poster)

MANUSCRIPTS FROM FELLOWSHIP: 1. Kim A, Devine B, Shirneshan E, Campbell J, Bansal A. Characterizing the Healthcare Resource Utilization and Costs in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration Stratified by Disease Severity (In Progress) 2. Kim A, Devine B, Roth J. Cost-effectiveness of first-line pembrolizumab + chemotherapy for advanced squamous and non-squamous non-small cell lung cancer from the US healthcare payer’s perspective (In Progress)

JAMIE TA, PHARMD, MS Jamie received her BS and PharmD from the University of California, San Diego. For the first year of the fellowship, Jamie worked under the mentorship of Drs. Beth Devine, Sean Sullivan, Lou Garrison, and Joshua Roth. At the University of Washington, she conducted a retrospective claims analysis to assess adherence, healthcare resource utilization, and costs among patients treated with antidepressants. Currently, she is working with Patrick Gillard and Amy Tung to support various projects in the CNS/psychiatry franchise. Jamie is excited to continue her training and apply her skills in real-world evidence, patient-reported outcomes research, and economic evaluation.

ABSTRACTS FROM FELLOWSHIP: 1. Ta JT, Roth J, Devine B, Garrison L. “Net Health Benefit“- ASCO vs. ICER Value Frameworks: Are We Talking about the Same Thing? ISPOR 2019, May 2019, New Orleans, LA. (Forum Presentation & Poster) 2. Sullivan SD, Ta JT, Carlson JJ, Hansen RN, Roth J, Veenstra DL, Ramsey SD. Challenges Estimating the Economic Value of Tissue-Agnostic Anti-Cancer Treatments. AMCP Nexus 2018, October 2018, Orlando, FL. (Poster) 3. Ta JT, Devine B. Impact of Antidepressant Non-Adherence and Non-Persistence on Healthcare Resource Utilization and Costs in Major Depressive Disorder: A Systematic Review. UW Corporate Advisory Board Meeting, September 2018, Seattle, WA. (Poster)

MANUSCRIPTS FROM FELLOWSHIP: 1. Ta JT, Sullivan SD, Tung A, Gillard PJ, Devine B. Healthcare Resource Utilization and Costs Associated with Non-Adherence to Pharmacotherapy for Major Depressive Disorder. (In Progress)

GHEOR Fellowship Program 2020-2022 8 PAST FELLOWS

Senior Manager, Global Health Economics and Outcomes Research • Allergan PLC, Irvine, CA SARA HIGA PharmD, MS KEY RESEARCH FROM FELLOWSHIP 1. Higa S, Devine B, Patel V, Baradaran S, Wang D, Bansal A. Psoriasis treatment patterns: a retrospective claims study. Curr Med Res Opin. 2017-2019 2019 Jun 17:1-7

CHIEMEKA Manager, Health Economics and Outcomes Research • Seattle Genetics, Bothell, WA IKE KEY RESEARCH FROM FELLOWSHIP MPH, PharmD, 1. Ike C, Marcum Z, Shewale A, Viswanathan H, Cotton S, Johnson C, Jackson J, Devine B. Treatment Patterns, Discontinuation and Switching of MS Acute Medications for Migraine: A Cross-Sectional Survey of Real-World Evidence from a Multi-Country Perspective. (In Progress) 2017-2019

Manager, Medical Affairs (HEOR) • Neurocrine Biosciences, San Diego, CA MICHAEL KEY RESEARCH FROM FELLOWSHIP SERBIN 1. Serbin M, Devine B, Campbell J, Basu A. Assessing the Societal Burden of Glaucoma Patients With vs. Without Physical or Mental PharmD, MS Comorbidities. (In Progress) 2016-2018

SHEILA Associate Health Economist, Evidence for Access (BioOncology) • Genentech, Inc., South San Francisco, CA SHAPOURI KEY RESEARCH FROM FELLOWSHIP PharmD, MS 1. Shapouri S, Devine EB, Keyloun KR, Gillard PJ, Sabbatini AK, Bansal A. Predicting Hospitalizations and Returns to the Emergency Department 2016-2018 30-Days Post Emergency Department Discharge Among Patients with Acute Bacterial Skin and Skin Structure Infections.

Senior Manager, Global Health Economics and Outcomes Research • Allergan PLC, Irvine, CA KEY RESEARCH FROM FELLOWSHIP 1. Baradaran S, Black D, Keyloun K, Hansen R, Gillard P, Devine B; The Impact of Acute Kidney Injury on the Risk of Mortality and Health Care SARAH Utilization Among Patients Treated With Polymyxins for Severe Gram-Negative Infections, Open Forum Infectious Diseases, Volume 5, Issue BARADARAN 8, 1 August 2018. PharmD, MS 2. Kagan R, Martin A, Sarri G, Guo Y, Baradaran S, Harrington A. The Burden of Illness Associated with Symptomatic Vulvovaginal Atrophy 2015-2017 (VVA): A Systematic Review. (In Progress) 3 Chin L, Devine B, Baradaran S, Keyloun K, Canestaro W, Pham J. Characterizing the Strength of Evidence in FDA Labels for Pharmacogenomic Biomarker-Guided Medication Use. AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science. 2017; 2017:30-39.

Senior Manager, Global Health Economics and Outcomes Research • Allergan PLC, Irvine, CA AMY KEY RESEARCH FROM FELLOWSHIP TUNG 1. Tung A, Hepp Z, Bansal A, Devine EB. Characterizing Health Care Utilization, Direct Costs, and Comorbidities Associated with Interstitial PharmD, MS Cystitis: A Retrospective Claims Analysis. J Manag Care Spec Pharm. 2017 Apr;23(4):474-482. 2015-2017 2. Dmochowski R, Brucker BM, Cole E, Kawahara S, Pulicharam R, Burk C, Tung A, Hale D. Economic Burden of Illness in Adult Patients with Nocturia. J Manag Care Spec Pharm. 2019 May;25(5):593-604.

Associate Director, Global Health Economics and Outcomes Research • Allergan PLC, Irvine, CA KEY RESEARCH FROM FELLOWSHIP KATELYN 1. Keyloun KR, Hansen R, Hepp Z, Gillard P, Thase M, Devine EB. Adherence and Persistence Across Antidepressant Therapeutic Class: A KEYLOUN Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD). CNS Drugs. 2017 May;31(5):421-432. PharmD, MS 2. Mathias P, Hendrix N, Wang W, Keyloun KR, Khelifi M, Tarcyzy-Hornoch P, Devine EB. Characterizing pharmacogenomic-guided medication 2014-2016 use with a clinical data repository. Clin Pharmacol Ther. 2017 Aug;102(2):340-348. 3. Chin L, Devine B, Baradaran S, Keyloun K, Canestaro W, Pham J. Characterizing the Strength of Evidence in FDA Labels for Pharmacogenomic Biomarker-Guided Medication Use. AMIA Joint Summits on Translational Science. 2017 Jul; eCollection.

VANESSA Associate Director, Global Health Economics and Outcomes Research • Allergan PLC, Irvine, CA SHIH KEY RESEARCH FROM FELLOWSHIP PharmD, MS 1. Shih V, Campbell J, Devine EB. The Association between Onset of Vision Impairment and Functional Limitations and Informal Caregiving 2014-2016 Requirements in Older Americans.

9 GHEOR Fellowship Program 2020-2022 Utilization Management and Specialty Coordinator • Kaiser Permanente of Washington, Seattle, WA TRACY YEP KEY RESEARCH FROM FELLOWSHIP PharmD, MS 1. Yep T, Patel VD, Slejko JF, Devine EB. Comparing Total and Disease Related Healthcare Cost for Glaucoma Patients by Disease Severity: A 2013-2015 Retrospective Claims Database Analysis. (In Progress)

Associate Director, Health Economics and Outcomes Research • Seattle Genetics, Seattle, WA KEY RESEARCH FROM FELLOWSHIP 1. Hepp Z, David DW, Gillard P, Varon SF, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with ZSOLT HEPP chronic migraine. Cephalalgia. 2015 May;35(6):478-88. PharmD, MS 2. Forrester S, Hepp Z, Roth J, Wirtz H, Devine EB. Cost-effectiveness of a computerized provider order entry system in improving medication 2012-2014 safety in ambulatory care. Value Health. 2014 Jun;17(4):340-9 3. Hepp Z, Dodick DW, Varon SF, Chia J, Matthew N, Gillard P, Hansen RN, Devine EB. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis. Cephalalgia. 2017 Apr;37(5):470-485. doi: 10.1177/0333102416678382. Epub 2016 Nov 12.

Senior Health Economist • Genentech, Inc., South San Francisco, CA KEY RESEARCH FROM FELLOWSHIP CHRIS 1. Stewart Williams JA, Wallick CJ, Byles JE, Doran CM.Assessing patterns of use of cardio-protective polypill component medicines in Australian WALLICK women. Drugs Aging (2013)30:193-203 PharmD, MS 2. Wallick CJ, Hansen RN, Campbell J, Kiss S, Kowalski JW, Sullivan SD. Comorbidity and Health Care Resource Use Among Commercially Insured 2012-2014 Non-Elderly Patients With Diabetic Macular Edema. Ophthalmic surgery, lasers & imaging retina. 2015 Jul-Aug;46(7):744-51 3. Wallick CJ, Sullivan SD, Hansen RN, Campbell JH, Kowalski JW. The Cost of Diabetic Macular Edema in a Commercially Insured Working Age Population Opthalmic Surg Lasers Imaging Retina. 2015 Jul-Aug;46(7):744-51

Consultant, Health Economics and Outcomes Research • Seattle, WA JOANNA KEY RESEARCH FROM FELLOWSHIP SANDERSON 1. JC Sanderson, EB Devine, RB Lipton, LM Bloudek, SF Varon, AM Blumenfeld, PJ Goadsby, DC Buse, SD Sullivan. Headache-related health PharmD, MS resource utilization in chronic and episodic migraine across six countries. J Neurol Neurosurg Psychiatry. 2013 Dec;84(12):1309-17 2011-2013 2. Messali A, Sanderson JC, Blumenfeld AM. Direct and Indirect Costs of Chronic and Episodic Migraine in the United States: A Web-Based Survey. Headache. 2016 Feb;56(2):306-22

Director, Health Economics and Outcomes Research EMEA • Kite Pharma, London, United Kingdom KEY RESEARCH FROM FELLOWSHIP VINCENT 1. Lin VW, Ringold S, Devine BE. Comparison of Ustekinumab with other Biologic Agents for Treatment of Moderate-to-Severe Psoriasis: A W. LIN Bayesian Network Meta-Analysis. Arch Dermatol. 2012 Dec;148(12):1403-10 PharmD, MS 2. Lin VW, Wright A, Flum DR, Alfonso RA, Garrison LP, Sullivan SD. Patients’ experience and outcomes after laparoscopic adjustable gastric 2010-2012 banding in Washington State. Surg Obes Relat Dis. 2013 Sep-Oct;9(5):701-5 3. Lin VW, Wong ES, Wright A. Association between health-related quality of life and body mass after adjustable gastric banding: a nonlinear approach. Value in Health. 2013 Jul;16(5):823-9

Executive Director, Global Health Economics and Outcomes Research • Allergan PLC, Irvine, CA PATRICK KEY RESEARCH FROM FELLOWSHIP GILLARD 1. Gillard PJ, Devine B, Varon SF, Liu L, Sullivan SD. Mapping from Disease- Specific Measures to Health-State Utility Values in Individuals with PharmD, MS Migraine. Value in Health 2012;15(3):485-94. 2009-2010 2. Doan QV, Brashear A, Gillard PJ, Varon SF, Turkel CC, Vandenburgh AM, Elovic EP. Relationship Between Disability Due to Upper-Limb Post- Stroke Spasticity and Health-Related Quality of Life and Caregiver Burden, PM&R 2012;4(1):4-10.

Director, Patient Reported Outcomes • The Janssen Pharmaceutical Companies of Johnson & Johnson, Raritan, NJ KATHARINE S. GRIES KEY RESEARCH FROM FELLOWSHIP PharmD, MS, PHD 1. Campbell JD, Gries KS, Watanabe JH, Ravelo A, Dmochowski RR, Sullivan SD. Treatment Success for Overactive Bladder with Urinary Urge Incontinence Refractory to Oral Antimuscarinics: A Review of Published Evidence. BMC Urology, 2009; 9(18) 2008-2010

Associate Professor of Clinical Pharmacy • UCSD Skaggs School of Pharmacy, La Jolla, CA KEY RESEARCH FROM FELLOWSHIP 1. Campbell JD, Gries KS, Watanabe JH, Ravelo A, Dmochowski RR, Sullivan SD. Treatment Success for Overactive Bladder with Urinary Urge JONATHAN H. Incontinence Refractory Oral Antimuscarinics. BMC Urology, 2009 Nov;20;9(18). WATANABE 2. Watanabe JH, Campbell JD, Ravelo A, Chancellor MB, Kowalski J, Sullivan SD. Cost Analysis of Interventions for Antimuscarinic Refractory PharmD, MS, PhD Patients with Overactive Bladder. Urology, 2010 Oct;76(4):835-40. 2007-2009 3. Sand P, Rovner E, Dmochoswki R, Watanabe JH, Oefelein MG. Once-daily Trospium Chloride 60 mg Extended Release is Safe and Effective in Subjects with the Overactive Bladder Syndrome who Use Multiple Concomitant Medications. Drugs Aging, 2011 Feb;1;28(2):151-60 4. Patel VD, Watanabe JH, Strauss JA, Dubey AT. Work productivity loss in patients with dry eye disease: an online survey. Curr Med Res Opin, 2011 May, 27(5):1041-8. GHEOR Fellowship Program 2020-2022 10 APPLICATION ELIGIBILITY Applicants for this fellowship must have a degree in pharmacy and have some research experience (preference will be given to those with a high academic standing). Excellent written and verbal communication skills are also essential. Applicants will be required to submit their curriculum vitae, a letter describing their career goals, and three letters of recommendation. Selection of fellows will be made by a steering committee composed of the University of Washington faculty members and representatives from Allergan.

DEADLINE ASHP Midyear Interview Application Deadline November 29, 2019

UW Graduate School Application Deadline December 13, 2019

APPLICATION INFORMATION Interested students must apply to the University of Washington Graduate School, and ALLERGAN FELLOWSHIP PROGRAMS register for Personnel Placement Services (PPS) at ASHP’s Midyear Clinical Meeting. The online application process can be found at: UNIVERSITY OF WASHINGTON University The Comparative Health Outcomes, https://sop.washington.edu/choice/graduate-education-training-programs/ Policy, and Economics (CHOICE) fellowships Institute University Seattle, WA Location

CONTACT INFORMATION Allergan Irvine, CA If you have any questions, please contact: Location UNIVERSITY OF WASHINGTON ALLERGAN PLC Program 2 years Marina Gano, M.Ed Amy Tung, PharmD, MS Length Graduate Program & Operations Manager Senior Manager Programs Global Health Economics and 1959 NE Pacific St. Suite H375, 2525 Dupont Drive Offered Outcomes Research Box 357630 Seattle, WA 98195 Irvine, CA 92612 E-Mail: [email protected] E-Mail: [email protected] Eligibility Degree in Pharmacy Phone: (206) 616-1383 Phone: (714) 246-5669